Nicola Klein to Papillomavirus Infections
This is a "connection" page, showing publications Nicola Klein has written about Papillomavirus Infections.
Connection Strength
2.008
-
Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine. Pediatrics. 2024 Aug 01; 154(2).
Score: 0.834
-
Extended surveillance to assess safety of 9-valent human papillomavirus vaccine. Hum Vaccin Immunother. 2022 12 30; 18(7):2159215.
Score: 0.187
-
Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes. JAMA Netw Open. 2021 04 01; 4(4):e214340.
Score: 0.166
-
Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses. J Infect Dis. 2020 03 02; 221(6):910-918.
Score: 0.154
-
Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics. 2019 12; 144(6).
Score: 0.151
-
Postlicensure safety surveillance of congenital anomaly and miscarriage among pregnancies exposed to quadrivalent human papillomavirus vaccine. Hum Vaccin Immunother. 2018 02 01; 14(2):412-419.
Score: 0.132
-
Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy. Obstet Gynecol. 2017 09; 130(3):599-608.
Score: 0.129
-
An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J. 2015 Sep; 34(9):983-91.
Score: 0.112
-
Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact. Cancer Causes Control. 2013 Feb; 24(2):403-7.
Score: 0.094
-
Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011. Vaccine. 2016 Jan 02; 34(1):167-71.
Score: 0.028
-
Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2012 Feb; 271(2):193-203.
Score: 0.022